A Multicenter Retrospective Study to Evaluate Safety and Efficacy of Tocopheryl Polyethylene Glycol Succinate Docetaxel in Various Cancers

Abstract

Introduction

In order to overcome the polysorbate induced hypersensitivity reactions with chemotherapy drugs, novel drug-delivery mechanisms have been developed in the last decade. D-alpha-tocopheryl polyethylene glycol succinate (TPGS) is formed by esterification of alpha-tocopheryl succinate and polyethylene glycol 1000.

Materials and Methods

This was a real-world retrospective analysis designed to evaluate safety and efficacy of TPGS-docetaxel in various cancers. Patients hospitalized between June 2018 and May 2019 were included in the data set. While the efficacy was assessed by the Response Evaluation Criteria in Solid Tumors criteria, safety was assessed by the National Cancer Institute Common Terminology Criteria-adverse event (AE) criteria.

Results

A total of 61 patients who received at least one dose of TPGS-docetaxel were incorporated into the analysis set. The dose of TPGS docetaxel ranged from 20 mg/m² to 120 mg/m², commonly prescribed dose being 75 mg/m². While 25 (40.98%) patients had a partial response, 17 (27.86%) patients had stable disease. Five (8.19%) patients progressed and 4 (6.55%) patients died during the chemotherapy, which was adjudicated to be unrelated to the drug as opined by the treating clinician. AE were reported in 42 patients in the safety data set. There were no AEs pertaining to hypersensitivity reported during the study. One AE of Grade 3 hand foot syndrome was encountered.

Conclusion

The preliminary evidence suggests that the novel TPGS-based docetaxel formulation is efficacious in various cancers, and importantly, it has an enhanced safety profile, as it is devoid of polysorbate 80 induced hypersensitivity reactions.

Keywords

Breast cancer - docetaxel - hypersensitivity reaction - non-small cell lung cancer - tocopheryl polyethylene glycol succinate

• References

• 1 Cortes JE, Pazdur R. Docetaxel. J Clin Oncol 1995; 13: 2643-55
• 2 Engels FK, Mathot RA, Verweij J. Alternative drug formulations of docetaxel: A review. Anticancer Drugs 2007; 18: 95-103
• 3 Picard M, Castells MC. Re-visiting hypersensitivity reactions to taxanes: A comprehensive review. Clin Rev Allergy Immunol 2015; 49: 177-91
• 4 Schwartzberg LS, Navari RM. Safety of polysorbate 80 in the oncology setting. Adv Ther 2018; 35: 754-67
• 5 Vasey PA, Atkinson R, Coleman R, Crqaford M, Cruikshank M, Eggleton P. et al. Docetaxel-carboplatin as first line chemotherapy for epithelial ovarian cancer. Br J Cancer 2001; 84: 170-8
• 6 Docetaxel Prescribing Information. United States Food and Drug Administration. 2014 https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/202356s000lbl.pdf Available from: [Last accessed on 2020 Jan 16]
• 7 Neophytou CM, Constantinou AI. Drug delivery innovations for enhancing the anticancer potential of Vitamin E isoforms and their derivatives. Biomed Res Int 2015; 2015: 584862
• 8 Zhang Z, Tan S, Feng SS. Vitamin E TPGS as a molecular biomaterial for drug delivery. Biomaterials 2012; 33: 4889-906
• 9 Guo Y, Luo J, Tan S, Otieno BO, Zhang Z. The applications of Vitamin E TPGS in drug delivery. Eur J Pharm Sci 2013; 49: 175-86
• 10 Dintaman JM, Silverman JA. Inhibition of P-glycoprotein by D-alpha-tocopheryl polyethylene glycol 1000 succinate (TPGS). Pharm Res 1999; 16: 1550-6
• 11 Muthu MS, Kulkarni SA, Raju A, Feng SS. Theranostic liposomes of TPGS coating for targeted co-delivery of docetaxel and quantum dots. Biomaterials 2012; 33: 3494-501
• 12 Zhu H, Chen H, Zeng X, Wang Z, Zhang X, Wu Y. et al. Co-delivery of chemotherapeutic drugs with Vitamin E TPGS by porous PLGA nanoparticles for enhanced chemotherapy against multi-drug resistance. Biomaterials 2014; 35: 2391-400
• 13 Mertens WC, Eisenhauer EA, Jolivet J, Ernst S, Moore M, Muldal A. Docetaxel in advanced renal carcinoma. A phase II trial of the National Cancer Institute of Canada Clinical Trials Group. Ann Oncol 1994; 5: 185-7
• 14 Pazdur R, Lassere Y, Soh LT, Ajani JA, Bready B, Soo E. et al. Phase II trial of docetaxel (Taxotere) in metastatic colorectal carcinoma. Ann Oncol 1994; 5: 468-70
• 15 Weiss RB, Donehower RC, Wiernik PH, Ohnuma T, Gralla RJ, Trump DL. et al. B. Hypersensitivity reactions from taxol. J Clin Oncol 1990; 8: 1263-8
• 16 Youk HJ, Lee E, Choi MK, Lee YJ, Chung JH, Kim SH. et al. Enhanced anticancer efficacy of alpha-tocopheryl succinate by conjugation with polyethylene glycol. J Control Release 2005; 107: 43-52
• 17 Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R. et al. New response evaluation criteria in solid tumours: Revised RECIST Guideline (version 1.1). Eur J Cancer 2009; 45: 228-47
• 18 Trotti A, Colevas AD, Setser A, Rusch V, Jaques D, Budach V. et al. CTCAE v3.0: Development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol 2003; 13: 176-81
• 19 Suvarna VR. Real world evidence (RWE) – Are we (RWE) ready?. Perspect Clin Res 2018; 9: 61-3
• 20 Figgitt DP, Wiseman LR. Docetaxel: An update of its use in advanced breast cancer. Drugs 2000; 59: 621-51
• 21 Sjöström J, Blomqvist C, Mouridsen H, Pluzanska A, Ottosson-Lönn S, Bengtsson NO. et al. Docetaxel compared with sequential methotrexate and 5-fluorouracil in patients with advanced breast cancer after anthracycline failure: A randomised phase III study with crossover on progression by the Scandinavian Breast Group. Eur J Cancer 1999; 35: 1194-201
• 22 Schellekens H, Hennink WE, Brinks V. The immunogenicity of polyethylene glycol: Facts and fiction. Pharm Res 2013; 30: 1729-34
• 23 Shahar E, Hassoun G, Pollack S. Effect of Vitamin E supplementation on the regular treatment of seasonal allergic rhinitis. Ann Allergy Asthma Immunol 2004; 92: 654-8
• 24 Yamada K, Hung P, Yoshimura K, Taniguchi S, Lim BO, Sugano M. Effect of unsaturated fatty acids and antioxidants on immunoglobulin production by mesenteric lymph node lymphocytes of Sprague-Dawley rats. J Biochem Tokyo 1996; 120: 138-44